×

Perseon Announces New Data for MicroThermX(R) in the Treatment of Large Liver Metastases From Colorectal Cancer and Large Hepatocellular Carcinoma From the 2015 Congress of Italian Society of Oncological Surgery (SICO) Conference

SALT LAKE CITY, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) ("Perseon" or the "Company") today announced that data supporting the use of the company's cutting edge microwave ablation technology, MicroThermX, was presented at the 38th Congress of Italian Society of Oncological Surgery (SICO) in Naples, Italy from September 9 – 12, 2015. The data included two posters, which looked at the use of multiple antennas in the treatment of large liver metastases from colorectal cancer and large hepatocellular carcinoma.

"These studies are just two examples that physicians are recognizing the unique properties of MicroThermX's Synchronous Wave Alignment Technology in the treatment of tumors, especially large tumors where energy ablation was previously viewed as ineffective," said Brian Meltzer, M.D., Chief Medical Officer and Vice President of Business Development. "These data reinforce MicroThermX as a safe and efficacious treatment option with low complication rates and the potential to reduce costly surgical resections of cancer."

  • Ablation of Large Liver Metastases from Colorectal Cancer Using Synchronous Insertion of Multiple Microwave Antennas evaluated the use of percutaneous energy ablation for the treatment of large (> 3 cm) colorectal cancer metastases (CRCmets) of the liver. Findings of this study show that there was a low complication rate with treatments and a high rate of complete necrosis. Complete response was shown in 92 percent (11/12) of patients treated with CRCmets.
  • Ablation of Large Hepatocellular Carcinoma (HCC) Using a New Multiple Antenna Microwave Device: Case Series evaluated the use of MicroThermX to achieve large volumes of necrosis in (HCC) by synchronous insertion and activation of multiple microwave antennas. Results showed that MicroThermX used in the treatment of (HCC) was safe and efficacious, with complete necrosis in 80 percent of HCC cases (8/10).

These data come at a time when Perseon continues to push for clinical results to reflect the safety and efficacy of microwave ablation, and to show the health economic advantages of using multiple, synchronized wave antennas at the time of the initial procedure.

About Perseon Corporation

Perseon Corporation invests its resources in fighting humanity's worst disease – cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy ablation solutions to healthcare providers and patients around the world. MicroThermX treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.

About MicroThermX

Perseon's energy ablation system, MicroThermX, has been developed as a stand-alone therapy that employs precision-guided microwave energy to ablate (burn) and destroy soft tissue. Perseon has developed extensive intellectual property and has established distribution in the United States, Europe and Asia.

Treatment sites include tumor ablation of the liver, kidney, brain, bone, lung, and other soft-tissue locations.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our focus on microwave ablation to create stockholder value and pursuit of our strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.

CONTACT: Jennifer R. Hoglin Vice President of Global Marketing Phone: (801) 972-5555 Email: jhoglin@perseonmedical.com

Source:Perseon Corporation